EuBiologics Co., Ltd.

A206650

KR7206650004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
13,540 ^KRW	+1.12%		-2.66%	+18.05%

Jan. 29	Zimbabwe launches door-to-door cholera vaccination campaign	RE
2023	Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	CI

Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd..

February 01, 2017

Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd. (KOSDAQ:A206650) on February 2, 2017. Under the terms, Global Health Investment Fund I, LLC acquired 1.3 million shares. Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC completed the acquisition of 6.19% stake in EuBiologics Co., Ltd. (KOSDAQ:A206650) on February 2, 2017.

Latest news about EuBiologics Co., Ltd.

Zimbabwe launches door-to-door cholera vaccination campaign	Jan. 29	RE
Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	23-07-14	CI
EuBiologics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea	22-02-03	CI
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd.	22-01-26	CI
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June	21-04-12	RE
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea	21-01-21	CI
EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index	19-09-23	CI
ATGC Co., Ltd. announced that it has received KRW 2.1 billion in funding from EuBiologics Co., Ltd.	19-01-09	CI
ATGC Co., Ltd. announced that it expects to receive KRW 2.1 billion in funding from EuBiologics Co., Ltd.	19-01-03	CI
EuBiologics Co., Ltd. announced that it has received KRW 30.00000351 billion in funding	18-04-29	CI
EuBiologics Co., Ltd. announced that it expects to receive KRW 30 billion in funding	18-02-11	CI
Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd..	17-02-01	CI
EuBiologics Co., Ltd. has completed an IPO in the amount of KRW 19.2 billion.	17-01-19	CI
EuBiologics Co., Ltd. has filed an IPO.	16-09-28	CI
EuBiologics Co., Ltd. announced that it has received $7.5 million in funding from Hanwha Investment Corp., Korea Investment Partners Co. Ltd., Oxford Bioscience Partners, Lion's Head Global Partners, Investment Arm	14-08-26	CI

Chart EuBiologics Co., Ltd.

Duration

Period

More charts

Company Profile

EuBiologics Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biopharmaceuticals. The Company operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
EUBIOLOGICS CO., LTD.	+18.05%	365M
CSL LIMITED	-3.79%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B

Biopharmaceuticals

EuBiologics Co., Ltd.

Equities

A206650

KR7206650004

Pharmaceuticals

Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd..

Latest news about EuBiologics Co., Ltd.

Chart EuBiologics Co., Ltd.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals